Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000801002 | SCV000940750 | uncertain significance | Hermansky-Pudlak syndrome 2 | 2023-04-06 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 646666). This variant has not been reported in the literature in individuals affected with AP3B1-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.002%). This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 442 of the AP3B1 protein (p.Cys442Tyr). |
Ambry Genetics | RCV002534666 | SCV003553657 | uncertain significance | Inborn genetic diseases | 2022-11-08 | criteria provided, single submitter | clinical testing | The c.1325G>A (p.C442Y) alteration is located in exon 13 (coding exon 13) of the AP3B1 gene. This alteration results from a G to A substitution at nucleotide position 1325, causing the cysteine (C) at amino acid position 442 to be replaced by a tyrosine (Y). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |